Introduction Pharma 4.0 refers to the digital transformation of pharmaceutical manufacturing, integrating advanced technologies such as AI, IoT ...

Shares of several major pharmaceutical companies slumped Wednesday morning as President Donald Trump threatened tariffs on ...

Experts say the tariffs are unlikely to bring back production of generic medicines, given their slim profit margins ...

Explore the impact of proposed Pharma tariffs on global markets as major stocks tumble. Click for my updated look at selected picks in the health industry.

Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS ...

Trump doubled down on plans to soon impose “major” pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.

Rising investments in healthcare diagnostics and pharmaceutical R&D ... steadily at a CAGR of 4.14% from 2023 to 2032, with the market size expected to expand from USD 154.83 million in 2023 ...

Biotech startups, investors sharpen focus on the commercial potential of drugs to attract acquirers, partners.